

# Suzanne V Arnold

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8792553/publications.pdf>

Version: 2024-02-01

142  
papers

5,990  
citations

66343

42  
h-index

82547

72  
g-index

144  
all docs

144  
docs citations

144  
times ranked

6820  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. <i>American Heart Journal</i> , 2022, 243, 232-239.	2.7	14
2	Patient-reported vs. physician-estimated symptoms before and after transcatheter aortic valve replacement. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 161-168.	4.0	5
3	Impact of micro- and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00321.	2.4	9
4	Impact of Frailty and Prefrailty on Outcomes of Transcatheter or Surgical Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, e011375.	3.9	14
5	Anxiety and Depression Following Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2022, 11, e024377.	3.7	3
6	Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. <i>BMC Endocrine Disorders</i> , 2022, 22, 111.	2.2	29
7	Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPEN-CTO Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024056.	3.7	5
8	Prognostic implications of baseline 6-min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E154-E160.	1.7	6
9	Impact of short-term complications of transcatheter aortic valve replacement on longer-term outcomes: results from the STS/ACC Transcatheter Valve Therapy Registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 208-213.	4.0	29
10	Type 2 diabetes and heart failure: insights from the global DISCOVER study. <i>ESC Heart Failure</i> , 2021, 8, 1711-1716.	3.1	10
11	Standardizing the standard: reporting health status in clinical trials. <i>European Journal of Heart Failure</i> , 2021, 23, 203-204.	7.1	0
12	Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. <i>Circulation: Heart Failure</i> , 2021, 14, e007564.	3.9	17
13	Practical Application of Patient-Reported Health Status Measures for Transcatheter Valve Therapies. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007187.	2.2	14
14	# SoMe for # IC : Optimal use of social media in interventional cardiology. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 97-106.	1.7	5
15	Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001585.	2.8	4
16	Interpretation of the Seattle Angina Questionnaire as an Outcome Measure in Clinical Trials and Clinical Care. <i>JAMA Cardiology</i> , 2021, 6, 593.	6.1	50
17	Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010258.	3.9	9
18	Incidence, Predictors, and Outcomes of Patients Discharged Home Versus Other Medical Facility After Transcatheter or Surgical Aortic Valve Replacement. <i>Structural Heart</i> , 2021, 5, 392-400.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Composite Metric for Benchmarking Site Performance in Transcatheter Aortic Valve Replacement: Results From the STS/ACC TVT Registry. <i>Circulation</i> , 2021, 144, 186-194.	1.6	26
20	Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 559-567.	4.1	6
21	Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation. <i>JACC: Heart Failure</i> , 2021, 9, 684-692.	4.1	8
22	Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008072.	2.2	2
23	Current Indications for Stenting: Symptoms or Survival? <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 14, 7.	1.0	0
24	Impact of Transcatheter Aortic Valve Replacement on Hospitalization Rates: Insights From Nationwide Readmission Database. <i>Journal of the American Heart Association</i> , 2021, 10, e022910.	3.7	1
25	Five-Year Health Status After Self-expanding Transcatheter or Surgical Aortic Valve Replacement in High-risk Patients With Severe Aortic Stenosis. <i>JAMA Cardiology</i> , 2021, 6, 97-101.	6.1	5
26	Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart Failure With Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2331-2341.	2.9	16
27	Use of non-HDL lipid-lowering medications in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00126.	2.4	1
28	Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2379-2390.	2.8	224
29	Very Early Changes in Quality of Life After Transcatheter Aortic Valve Replacement: Results From the 3M TAVR Trial. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1573-1578.	0.8	19
30	Heart failure documentation in outpatients with diabetes and volume overload: an observational cohort study from the Diabetes Collaborative Registry. <i>Cardiovascular Diabetology</i> , 2020, 19, 212.	6.8	3
31	Site-Level Variability in 30-Day Patient Outcomes After Transcatheter Mitral Valve Repair in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006878.	2.2	0
32	Can we improve the appropriateness of PCI?. <i>Heart</i> , 2020, 106, 405-406.	2.9	1
33	Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2099-2106.	2.8	24
34	Priorities for Patient-Centered Research in Valvular Heart Disease: A Report From the National Heart, Lung, and Blood Institute Working Group. <i>Journal of the American Heart Association</i> , 2020, 9, e015975.	3.7	29
35	Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction. <i>JAMA Network Open</i> , 2020, 3, e203032.	5.9	12
36	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e779-e806.	1.6	157

#	ARTICLE	IF	CITATIONS
37	Abstract 13: Patient-reported Health Status Changes are Associated With Subsequent Clinical Outcomes After Transcatheter Valve Therapies: Insights From the Sts/tvt Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, .	2.2	1
38	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 261-266.	4.4	7
39	Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "research-to-practice" project from the diabetes collaborative registry. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 393-396.	4.4	2
40	Association of Smoking Status With Long-Term Mortality and Health Status After Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011766.	3.7	4
41	Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2074-2084.	2.8	19
42	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 933-941.	4.1	31
43	In-Hospital Costs and Costs of Complications of Chronic Total Occlusion Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 323-331.	2.9	28
44	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2019, 140, 618-620.	1.6	96
45	Association of Changes in Heart Failure Treatment With Patients' Health Status. <i>JACC: Heart Failure</i> , 2019, 7, 615-625.	4.1	20
46	De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status. <i>American Heart Journal</i> , 2019, 214, 1-8.	2.7	1
47	Integrating Quality of Life and Survival Outcomes in Cardiovascular Clinical Trials: Results From the PARTNER Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005420.	2.2	14
48	Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2123-2132.	2.8	94
49	Development and Application of a Risk Prediction Model for In-Hospital Stroke After Transcatheter Aortic Valve Replacement: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1097-1103.	1.3	49
50	Anti-anginal medication titration among patients with residual angina 6-months after chronic total occlusion percutaneous coronary intervention: insights from OPEN CTO registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 5, 370-379.	4.0	4
51	Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter 2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1985-1989.	4.4	15
52	Impact of Short-Term Complications on Mortality and Quality of Life After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 362-369.	2.9	74
53	Association Between Diastolic Dysfunction and Health Status Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2476-2484.	2.9	5
54	Change in Hospitalization Rates Following Transcatheter Mitral Valve Repair. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008342.	3.9	6

#	ARTICLE	IF	CITATIONS
55	420-P: Micro- and Macrovascular Events in Patients with T2Dâ€”Results from the Global DISCOVER Study. <i>Diabetes</i> , 2019, 68, .	0.6	2
56	Calculating Risk for Poor Outcomes After Transcatheter Aortic Valve Replacement. <i>Journal of Clinical Outcomes Management</i> , 2019, 26, 125-129.	1.7	0
57	Burden of cardioâ€œrenalâ€œmetabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2000-2003.	4.4	42
58	Use of Intensive Glycemic Management in Older Adults with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1190-1194.	2.6	53
59	Validation of the Seattle angina questionnaire in women with ischemic heart disease. <i>American Heart Journal</i> , 2018, 201, 117-123.	2.7	25
60	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2628-2639.	2.8	370
61	Inclusion of Functional Status Measuresâ€”the Risk Adjustment of 30-Day Mortality After Transcatheter Aortic Valveâ€”Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 581-589.	2.9	49
62	Constraint approaches to the estimation of relative risk. <i>Statistical Methods in Medical Research</i> , 2018, 27, 3436-3446.	1.5	4
63	Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year. <i>JAMA Cardiology</i> , 2018, 3, 1151.	6.1	36
64	The Evolution of Patient-Reported Outcomes in Clinical Trials and Management of Patients With Coronary Artery Disease. <i>JAMA Cardiology</i> , 2018, 3, 1035.	6.1	20
65	Predicting Quality of Life at 1 Year After Transcatheter Aortic Valve Replacement in a Real-World Population. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004693.	2.2	35
66	Effect of SAPIEN 3 Transcatheter Valve Implantation on Health Status in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1188-1198.	2.9	25
67	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). <i>American Heart Journal</i> , 2018, 203, 25-29.	2.7	29
68	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1035-1039.	2.3	3
69	Goals of Therapy. , 2018, , 227-233.		1
70	Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population. <i>JAMA Cardiology</i> , 2017, 2, 409.	6.1	110
71	Global Outcome in Patients With Left Ventricular Assist Devices. <i>American Journal of Cardiology</i> , 2017, 119, 1069-1073.	1.6	13
72	Personalizing the Intensity of Blood Pressure Control. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	37

#	ARTICLE	IF	CITATIONS
73	The Impact of Cardiovascular Drugs on Glycemic Control: A Review. <i>Endocrine Practice</i> , 2017, 23, 363-371.	2.1	5
74	Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 169-176.	0.8	9
75	Frail Elderly, the Ideal Patients for MitraClip. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1930-1931.	2.9	5
76	Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 1315.	6.1	126
77	Precision Medicine for Cardiac Resynchronization. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	14
78	Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	9
79	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry <sup>Â®</sup> . <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	21
80	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDRA <sup>®</sup> Research to Practice project. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1637-1645.	1.8	109
81	Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trial. <i>American Heart Journal</i> , 2017, 194, 39-48.	2.7	30
82	Dyspnea Among Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	21
83	The Impact of De-escalation of Antianginal Medications on Health Status After Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	4
84	Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. <i>JAMA Cardiology</i> , 2017, 2, 837.	6.1	105
85	The prevalence and management of angina among patients with chronic coronary artery disease across US outpatient cardiology practices: insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study. <i>Clinical Cardiology</i> , 2017, 40, 6-10.	1.8	31
86	Health Status Outcomes in Patients With Acute Myocardial Infarction After Rehospitalization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 777-784.	2.2	7
87	The Association Between Complementary and Alternative Medicine and Health Status Following Acute Myocardial Infarction. <i>Clinical Cardiology</i> , 2016, 39, 440-445.	1.8	3
88	Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2349-2358.	2.8	97
89	Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: Insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study. <i>American Heart Journal</i> , 2016, 175, 94-100.	2.7	47
90	Predicting the Benefit of Statins in Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 191-193.	2.2	1

#	ARTICLE	IF	CITATIONS
91	Frequency of Poor Outcome (Death or Poor Quality of Life) After Left Ventricular Assist Device for Destination Therapy. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	54
92	Predictors of Physician Under-Recognition of Angina in Outpatients With Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 554-559.	2.2	53
93	Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1868-1877.	2.8	128
94	Association Between Cardiac Rehabilitation Participation and Health Status Outcomes After Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2016, 1, 980.	6.1	31
95	Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. <i>Diabetes Care</i> , 2016, 39, e99-e101.	8.6	29
96	Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 372-379.	2.2	22
97	Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 2, 208-214.	4.0	32
98	Should Transcatheter Aortic Valve Replacement Be Performed in Nonagenarians?. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1387-1395.	2.8	79
99	Assessing Quality of Life and Medical Care in Chronic Angina: An Internet Survey. <i>Interactive Journal of Medical Research</i> , 2016, 5, e12.	1.4	3
100	Abstract 11: Comparison of Patient Reported Angina with Provider Assigned Canadian Cardiovascular Society Angina Class Before and After Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, .	2.2	3
101	Prediction of residual angina after percutaneous coronary intervention. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2015, 1, 23-30.	4.0	30
102	Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 779-787.	1.8	15
103	Incidence and Predictors of Cognitive Decline in Patients with Left Ventricular Assist Devices. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 285-291.	2.2	37
104	Association of Patient-Reported Health Status With Long-Term Mortality After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002875.	3.9	47
105	Health Status After Transcatheter Aortic Valve Replacement in Patients at Extreme Surgical Risk. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 315-323.	2.9	76
106	Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: Results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. <i>American Heart Journal</i> , 2015, 170, 753-759.e2.	2.7	5
107	Relation of Frailty to Outcomes After Transcatheter Aortic Valve Replacement (from the PARTNER) <i>Tj ETQq1 1 0.784314 rgBT /Overlook</i>	1.6	206
108	Recognition of Incident Diabetes Mellitus During an Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 260-267.	2.2	16

#	ARTICLE	IF	CITATIONS
109	Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction. <i>Heart</i> , 2015, 101, 800-807.	2.9	52
110	Association of Smoking Status With Angina and Health-Related Quality of Life After Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 493-500.	2.2	34
111	Health Status After Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Increased Surgical Risk. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1207-1217.	2.9	100
112	Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement. <i>Heart</i> , 2015, 101, 1656-1664.	2.9	32
113	Temporal Trends in Quality of Life Outcomes After Transapical Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 338-346.	2.2	25
114	Costs of Periprocedural Complications in Patients Treated With Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 829-836.	3.9	76
115	Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 844-850.	2.2	81
116	The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000046.	2.8	9
117	Derivation and Validation of a Risk Standardization Model for Benchmarking Hospital Performance for Health-Related Quality of Life Outcomes After Acute Myocardial Infarction. <i>Circulation</i> , 2014, 129, 313-320.	1.6	43
118	Effects of Ranolazine on Quality of Life Among Patients With Diabetes Mellitus and Stable Angina. <i>JAMA Internal Medicine</i> , 2014, 174, 1403.	5.1	20
119	Hospital-Level Variation in Angina and Mortality at 1 Year After Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 851-856.	2.2	13
120	Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Diabetes and Severe Aortic Stenosis at High Risk for Surgery. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1090-1099.	2.8	61
121	Patterns of Statin Initiation, Intensification, and Maximization Among Patients Hospitalized With an Acute Myocardial Infarction. <i>Circulation</i> , 2014, 129, 1303-1309.	1.6	62
122	Predictors of Poor Outcomes After Transcatheter Aortic Valve Replacement. <i>Circulation</i> , 2014, 129, 2682-2690.	1.6	214
123	Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c. <i>American Heart Journal</i> , 2014, 168, 457-465.e2.	2.7	17
124	Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. <i>American Heart Journal</i> , 2014, 168, 466-470.e1.	2.7	58
125	The hostile heart: anger as a trigger for acute cardiovascular events. <i>European Heart Journal</i> , 2014, 35, 1359-1360.	2.2	3
126	Type of $\beta$ -blocker use among patients with versus without diabetes after myocardial infarction. <i>American Heart Journal</i> , 2014, 168, 273-279.e1.	2.7	14



#	ARTICLE	IF	CITATIONS
127	Beyond Medication Prescription as Performance Measures. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1791-1801.	2.8	102
128	The Reliability and Prognosis of In-Hospital Diagnosis of Metabolic Syndrome in the Setting of Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, 704-708.	2.8	15
129	Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2038-2045.	2.8	184
130	Relation Between Six-Minute Walk Test Performance and Outcomes After Transcatheter Aortic Valve Implantation (from the PARTNER Trial). <i>American Journal of Cardiology</i> , 2013, 112, 700-706.	1.6	70
131	Preoperative Anxiety as a Predictor of Mortality and Major Morbidity in Patients Aged >70 Years Undergoing Cardiac Surgery. <i>American Journal of Cardiology</i> , 2013, 111, 137-142.	1.6	148
132	How to Define a Poor Outcome After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 591-597.	2.2	96
133	Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2013, 6, 1139-1146.	3.9	130
134	Use of the Kansas City Cardiomyopathy Questionnaire for Monitoring Health Status in Patients With Aortic Stenosis. <i>Circulation: Heart Failure</i> , 2013, 6, 61-67.	3.9	137
135	Perceived Stress in Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1756-1763.	2.8	141
136	Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 467-476.	2.2	115
137	Statin Use in Outpatients With Obstructive Coronary Artery Disease. <i>Circulation</i> , 2011, 124, 2405-2410.	1.6	62
138	Economic Impact of Angina After an Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 344-353.	2.2	107
139	Psychosocial Modulators of Angina Response to Myocardial Ischemia. <i>Circulation</i> , 2009, 120, 126-133.	1.6	40
140	Implementing an innovative consent form: the PREDICT experience. <i>Implementation Science</i> , 2008, 3, 58.	6.9	8
141	Effects of Ranolazine on Disease-Specific Health Status and Quality of Life Among Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 107-115.	2.2	44
142	Converting the Informed Consent From a Perfunctory Process to an Evidence-Based Foundation for Patient Decision Making. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 21-28.	2.2	83